CUSIP: 64052L106
Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
10,320,143
-
Share change
-
-6,104,845
-
Total reported value
-
$6,447,006
-
Put/Call ratio
-
20%
-
Price per share
-
$0.62
-
Number of holders
-
31
-
Value change
-
-$3,371,543
-
Number of buys
-
11
-
Number of sells
-
12
Quarterly Holders Quick Answers
What is CUSIP 64052L106?
CUSIP 64052L106 identifies NEOS - NEOS THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2021
-
Previous quarter:
Q3 2020
Recent filing periods for CUSIP 64052L106:
Institutional Holders of NEOS THERAPEUTICS INC - COM (NEOS) as of Q4 2020
As of 31 Dec 2020,
NEOS THERAPEUTICS INC - COM (NEOS) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,320,143 shares.
The largest 10 holders included
Stonepine Capital Management, LLC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, GOLDMAN SACHS GROUP INC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), SUSQUEHANNA INTERNATIONAL GROUP, LLP, BRIDGEWAY CAPITAL MANAGEMENT, LLC, and NORTHERN TRUST CORP.
This page lists
31
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.